| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 重庆智翔金泰生物制药股份有限公司(简称智翔金泰)成立于2015年,位于重庆国际生物城,是一家以抗体药物发现技术为驱动的创新型生物制药企业聚焦自身免疫性疾病、感染性疾病以及肿瘤等治疗领域,从事抗体药物的研发、生产及商业化。智翔金泰始终关注未被满足的临床需求,秉承“为病人做好药”的宗旨,持续为患者提供可信赖和可负担的创新生物药。 | ||||||||||||||||||||||||
| Main Business | 抗体药物的研发、生产与销售。 | ||||||||||||||||||||||||
| Legal Representative | 单继宽 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李春生 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 信永中和会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
| Tel No | 023-61758666转8621 | ||||||||||||||||||||||||
| Fax No | 023-61758011 | ||||||||||||||||||||||||
| Website | www.genrixbio.com | ||||||||||||||||||||||||
| irm@genrixbio.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/06/2023 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -2.500 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.593 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.143B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |